

Daniele Roberto Giacobbe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8322887/publications.pdf>

Version: 2024-02-01

194
papers

6,911
citations

81743

39
h-index

82410

72
g-index

198
all docs

198
docs citations

198
times ranked

7849
citing authors

#	ARTICLE	IF	CITATIONS
1	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antimicrobial Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i> , 2019, 39, 10-39.	1.2	545
2	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2133-2143.	1.3	434
3	The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13209.	1.7	285
4	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	3.9	278
5	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-producing <i>K. pneumoniae</i> . <i>Clinical Infectious Diseases</i> , 2019, 68, 355-364.	2.9	265
6	Treatment of Infections Due to MDR Gram-Negative Bacteria. <i>Frontiers in Medicine</i> , 2019, 6, 74.	1.2	211
7	Bloodstream infections in critically ill patients with COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13319.	1.7	203
8	COVID-19-Associated Pulmonary Aspergillosis, March-August 2020. <i>Emerging Infectious Diseases</i> , 2021, 27, 1077-1086.	2.0	175
9	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients: a multinational observational study by the European Confederation of Medical Mycology. <i>Clinical Microbiology and Infection</i> , 2022, 28, 580-587.	2.8	133
10	Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1664-1676.	2.9	130
11	Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020, 279, 103455.	0.7	129
12	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , 2019, 23, 219.	2.5	123
13	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. <i>Clinical Infectious Diseases</i> , 2021, 72, S121-S127.	2.9	109
14	Ceftolozane/tazobactam: place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 307-320.	2.0	100
15	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 555.	1.0	93
16	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <i>PLoS ONE</i> , 2020, 15, e0237831.	1.1	85
17	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1537-1544.	2.8	84
18	Spread of Carbapenem-Resistant Gram-Negatives and <i>Candida auris</i> during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship?. <i>Microorganisms</i> , 2021, 9, 95.	1.6	77

#	ARTICLE	IF	CITATIONS
19	Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , 2020, 9, 2780.	1.0	71
20	Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment. <i>European Journal of Internal Medicine</i> , 2019, 62, 1-6.	1.0	70
21	Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 585-596.	2.0	68
22	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. <i>Antibiotics</i> , 2020, 9, 71.	1.5	68
23	Bloodstream infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> : Clinical features, therapy and outcome from a multicenter study. <i>Journal of Infection</i> , 2019, 79, 130-138.	1.7	67
24	Combined use of serum (1,3)- β -D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. <i>Critical Care</i> , 2017, 21, 176.	2.5	65
25	Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis. <i>Journal of Infection</i> , 2020, 81, 131-146.	1.7	62
26	Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 25, 268-281.	0.9	62
27	Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia. <i>Critical Care</i> , 2021, 25, 81.	2.5	59
28	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 244-248.	1.1	55
29	Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications. <i>Clinical Microbiology and Infection</i> , 2020, 26, 713-722.	2.8	54
30	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <sc>FUN</sc>gal infections Definitions in <sc>ICU</sc> patients (<sc>FUNDICU</sc>) project. <i>Mycoses</i> , 2019, 62, 310-319.	1.8	53
31	<i>Candida auris</i> Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk Factors. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1149-1160.	1.8	51
32	Molecular Epidemiological Investigation of a Nosocomial Cluster of <i>C. auris</i> : Evidence of Recent Emergence in Italy and Ease of Transmission during the COVID-19 Pandemic. <i>Journal of Fungi (Basel)</i> , 2021, 7, 1010.	1.8	50
33	Meropenem for treating KPC-producing <i>Klebsiella pneumoniae</i> bloodstream infections: Should we get to the PK/PD root of the paradox?. <i>Virulence</i> , 2017, 8, 66-73.	1.8	49
34	Dengue: Status of current and under development vaccines. <i>Reviews in Medical Virology</i> , 2020, 30, e2101.	3.9	49
35	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa139.	0.4	49
36	Neurological Manifestations of Severe SARS-CoV-2 Infection: Potential Mechanisms and Implications of Individualized Mechanical Ventilation Settings. <i>Frontiers in Neurology</i> , 2020, 11, 845.	1.1	46

#	ARTICLE	IF	CITATIONS
37	Changing epidemiology of candidaemia: Increase in fluconazole-resistant <i>Candida parapsilosis</i> . <i>Mycoses</i> , 2020, 63, 361-368.	1.8	45
38	Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. <i>Critical Care</i> , 2021, 25, 111.	2.5	45
39	Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1219-1236.	1.3	44
40	Measles: An Overview of a Re-Emerging Disease in Children and Immunocompromised Patients. <i>Microorganisms</i> , 2020, 8, 276.	1.6	44
41	Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020, 282, 103529.	0.7	43
42	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. <i>PLoS Pathogens</i> , 2021, 17, e1009448.	2.1	43
43	Diagnosis and treatment of COVID-19 associated pulmonary aspergillosis in critically ill patients: results from a European confederation of medical mycology registry. <i>Intensive Care Medicine</i> , 2021, 47, 1158-1160.	3.9	43
44	Will new antimicrobials overcome resistance among Gram-negatives?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 909-922.	2.0	42
45	Ceftobiprole: drug evaluation and place in therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 689-698.	2.0	42
46	Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 109-118.	2.0	41
47	Trends in the annual incidence of carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infections: a 8-year retrospective study in a large teaching hospital in northern Italy. <i>BMC Infectious Diseases</i> , 2015, 15, 415.	1.3	40
48	Changes in the relative prevalence of candidaemia due to non- <i>Candida albicans</i> <i>Candida</i> species in adult inpatients: A systematic review, meta-analysis and meta-regression. <i>Mycoses</i> , 2020, 63, 334-342.	1.8	40
49	History of schistosomiasis (bilharziasis) in humans: from Egyptian medical papyri to molecular biology on mummies. <i>Pathogens and Global Health</i> , 2018, 112, 268-273.	1.0	39
50	Lung distribution of gas and blood volume in critically ill COVID-19 patients: a quantitative dual-energy computed tomography study. <i>Critical Care</i> , 2021, 25, 214.	2.5	39
51	Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. <i>Infection</i> , 2017, 45, 849-856.	2.3	37
52	Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance. <i>Antibiotics</i> , 2020, 9, 632.	1.5	37
53	Post-operative abdominal infections: epidemiology, operational definitions, and outcomes. <i>Intensive Care Medicine</i> , 2020, 46, 163-172.	3.9	36
54	Neurological Complications and Noninvasive Multimodal Neuromonitoring in Critically Ill Mechanically Ventilated COVID-19 Patients. <i>Frontiers in Neurology</i> , 2020, 11, 602114.	1.1	36

#	ARTICLE	IF	CITATIONS
55	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Clinical Microbiology and Infection</i> , 2020, 26, 880-894.	2.8	36
56	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106611.	1.1	36
57	Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteraemia in colonized patients: results from a retrospective multicentre study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 663-669.	1.3	32
58	<i>Mycobacterium chimaera</i> infections: An update. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 199-205.	0.8	32
59	Early Detection of Sepsis With Machine Learning Techniques: A Brief Clinical Perspective. <i>Frontiers in Medicine</i> , 2021, 8, 617486.	1.2	32
60	Coagulative Disorders in Critically Ill COVID-19 Patients with Acute Distress Respiratory Syndrome: A Critical Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 140.	1.0	32
61	Efficacy and Safety of Meropenem+Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis. <i>Advances in Therapy</i> , 2019, 36, 1771-1777.	1.3	31
62	Aortic cross-clamp time and cardiopulmonary bypass time: prognostic implications in patients operated on for infective endocarditis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 27, 328-335.	0.5	30
63	Use of colistin in adult patients: A cross-sectional study. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 43-49.	0.9	29
64	Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2020, 71, 1799-1801.	2.9	28
65	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021, 10, 1837-1885.	1.8	28
66	Epidemiology, management, and outcome of carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infections in hospitals within the same endemic metropolitan area. <i>Journal of Infection and Public Health</i> , 2018, 11, 171-177.	1.9	27
67	COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges. <i>Intensive Care Medicine</i> , 2021, 47, 1339-1340.	3.9	27
68	The role of fosfomycin for multidrug-resistant gram-negative infections. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 617-625.	1.3	26
69	Mould Infections of Traumatic Wounds: A Brief Narrative Review. <i>Infectious Diseases and Therapy</i> , 2020, 9, 1-15.	1.8	25
70	Therapeutic options for difficult-to-treat <i>Acinetobacter baumannii</i> infections: a 2020 perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 167-177.	0.9	25
71	The safety of treatment options for acute bacterial skin and skin structure infections. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 635-650.	1.0	24
72	Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry. <i>European Heart Journal</i> , 2022, 43, 2770-2780.	1.0	24

#	ARTICLE	IF	CITATIONS
73	Risk factors for infections due to carbapenem-resistant <i>Klebsiella pneumoniae</i> after open heart surgery. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 23, 762-768.	0.5	23
74	Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment. <i>Scientific Reports</i> , 2018, 8, 11968.	1.6	23
75	Diagnosis and Treatment of Candidemia in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 524-539.	0.8	23
76	Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy. <i>BMC Infectious Diseases</i> , 2021, 21, 353.	1.3	23
77	Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units. <i>Critical Care</i> , 2021, 25, 155.	2.5	23
78	Enterococcal bloodstream infections in critically ill patients with COVID-19: a case series. <i>Annals of Medicine</i> , 2021, 53, 1779-1786.	1.5	22
79	Bloodstream infections in internal medicine. <i>Virulence</i> , 2016, 7, 353-365.	1.8	21
80	Risk factors for candidaemia in hospitalized patients with liver cirrhosis: a multicentre caseâ€“controlâ€“control study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 276-282.	2.8	21
81	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4697-4711.	1.1	21
82	Challenges and research priorities to progress the impact of antimicrobial stewardship. <i>Drugs in Context</i> , 2019, 8, 1-15.	1.0	21
83	New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 280-294.	0.8	21
84	Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1862-1871.	1.3	20
85	Use of 1,3-Î²-D-glucan in invasive fungal diseases in hematology patients. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 1101-1112.	2.0	20
86	Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts. <i>Critical Care</i> , 2020, 24, 117.	2.5	19
87	Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions. <i>Archives of Medical Research</i> , 2021, 52, 817-827.	1.5	19
88	The Impact of Carbapenem Resistance on Mortality in Patients With <i>Klebsiella pneumoniae</i> Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients. <i>Infectious Diseases and Therapy</i> , 2021, 10, 541-558.	1.8	18
89	Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2651.	1.0	18
90	Role of fecal microbiota transplantation in inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2018, 19, 322-334.	0.7	17

#	ARTICLE	IF	CITATIONS
91	<p><p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>. Core Evidence, 2019, Volume 14, 31-40.</p>	4.7	17
92	<p>Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria. Future Microbiology, 2020, 15, 1489-1505.</p>	1.0	17
93	<p>Zinc Chelators as Carbapenem Adjuvants for Metallo-β-Lactamase-Producing Bacteria: <i>In Vitro</i> and <i>In Vivo</i> Evaluation. Microbial Drug Resistance, 2020, 26, 1133-1143.</p>	0.9	17
94	<p>The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome. Frontiers in Medicine, 2021, 8, 671714.</p>	1.2	17
95	<p>Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i>: a multicentre study. JAC-Antimicrobial Resistance, 2022, 4, dlac022.</p>	0.9	17
96	<p>Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a <i>Post Hoc</i> Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study. Journal of Clinical Microbiology, 2022, 60, e0229821.</p>	1.8	17
97	<p>Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant <i>Staphylococcus aureus</i>: advances in phase I and II trials. Expert Opinion on Investigational Drugs, 2020, 29, 495-506.</p>	1.9	16
98	<p>Methicillin-resistant Staphylococcus aureus lung infection in coronavirus disease 2019: how common?. Current Opinion in Infectious Diseases, 2022, 35, 149-162.</p>	1.3	16
99	<p>Respiratory Fungal Diseases in Adult Patients With Cystic Fibrosis. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2019, 13, 117954841984993.</p>	0.5	15
100	<p>Recent advances and future perspectives in the pharmacological treatment of <i>Candida auris</i> infections. Expert Review of Clinical Pharmacology, 2021, 14, 1205-1220.</p>	1.3	15
101	<p>Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. BMC Infectious Diseases, 2014, 14, 725.</p>	1.3	14
102	<p>Machine Learning and Multidrug-Resistant Gram-Negative Bacteria: An Interesting Combination for Current and Future Research. Antibiotics, 2020, 9, 54.</p>	1.5	14
103	<p>Reactivation of Herpes Simplex Virus Type 1 (HSV-1) Detected on Bronchoalveolar Lavage Fluid (BALF) Samples in Critically Ill COVID-19 Patients Undergoing Invasive Mechanical Ventilation: Preliminary Results from Two Italian Centers. Microorganisms, 2022, 10, 362.</p>	1.6	14
104	<p>Clinical interpretation of an interpretable prognostic model for patients with COVID-19. Nature Machine Intelligence, 2021, 3, 16-16.</p>	8.3	13
105	<p>Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.</p>	1.8	13
106	<p>Anaerobic bloodstream infections in Italy (ITANAEROBY): A 5-year retrospective nationwide survey. Anaerobe, 2022, 75, 102583.</p>	1.0	13
107	<p>Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1707-1709.</p>	1.3	12
108	<p>Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 413-417.</p>	1.3	12

#	ARTICLE	IF	CITATIONS
109	A look at the clinical, economic, and societal impact of antimicrobial resistance in 2020. Expert Opinion on Pharmacotherapy, 2020, 21, 2067-2071.	0.9	12
110	Early Effects of Passive Leg-Raising Test, Fluid Challenge, and Norepinephrine on Cerebral Autoregulation and Oxygenation in COVID-19 Critically Ill Patients. Frontiers in Neurology, 2021, 12, 674466.	1.1	12
111	Understanding the pathophysiology of typical acute respiratory distress syndrome and severe COVID-19. Expert Review of Respiratory Medicine, 2022, , 1-10.	1.0	12
112	Current pharmacotherapy for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) pneumonia. Expert Opinion on Pharmacotherapy, 2022, 23, 361-375.	0.9	12
113	Performance of serum (1,3)- β -D-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. Mycoses, 2018, 61, 650-655.	1.8	11
114	Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies. Infectious Diseases and Therapy, 2020, 9, 481-494.	1.8	11
115	Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections. Current Opinion in Infectious Diseases, 2020, 33, 110-120.	1.3	11
116	Systemic fibrinolysis for acute pulmonary embolism complicating acute respiratory distress syndrome in severe COVID-19: a case series. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 78-80.	1.4	11
117	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. Infectious Diseases and Therapy, 2021, 10, 387-398.	1.8	11
118	Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria. Expert Review of Anti-Infective Therapy, 2021, 19, 983-991.	2.0	11
119	Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study. BMC Infectious Diseases, 2021, 21, 806.	1.3	11
120	Isolation of Candida auris from invasive and non-invasive samples of a patient suffering from vascular disease, Italy, July 2019. Eurosurveillance, 2019, 24, .	3.9	11
121	Skin manifestations in patients with coronavirus disease 2019. Current Opinion in Infectious Diseases, 2022, 35, 88-94.	1.3	11
122	Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression. Vaccines, 2022, 10, 1141.	2.1	11
123	Bordetella holmesii endocarditis in a patient with systemic lupus erythematosus treated with immunosuppressive agents. Journal of Chemotherapy, 2012, 24, 240-242.	0.7	10
124	Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections. Journal of Clinical Medicine, 2021, 10, 1127.	1.0	10
125	Treatment of extended-spectrum β -lactamases infections: what is the current role of new β -lactams/ β -lactamase inhibitors?. Current Opinion in Infectious Diseases, 2020, 33, 474-481.	1.3	10
126	<i>Aspergillus</i> PCR in bronchoalveolar lavage: diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patients. Mycoses, 2022, 65, 411-418.	1.8	10

#	ARTICLE	IF	CITATIONS
127	Pregnancy outcomes following exposure to efavirenz-based antiretroviral therapy in the Republic of Congo. <i>New Microbiologica</i> , 2015, 38, 185-92.	0.1	10
128	First Report of Chronic Pulmonary Infection by KPC-3-Producing and Colistin-Resistant <i>Klebsiella pneumoniae</i> Sequence Type 258 (ST258) in an Adult Patient with Cystic Fibrosis: TABLE 1. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1442-1444.	1.8	9
129	Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105921.	1.1	9
130	Role of new antibiotics in extended-spectrum β -lactamase-, AmpC- infections. <i>Current Opinion in Infectious Diseases</i> , 2021, Publish Ahead of Print, 748-755.	1.3	9
131	The role of new antimicrobials for Gram-negative infections in daily clinical practice. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 495-500.	1.3	9
132	New Insights into Infections due to Multidrug Resistant Gram Negative Bacteria: The Interplay between Lab and Clinic. <i>BioMed Research International</i> , 2018, 2018, 1-3.	0.9	8
133	A look at clinical trial design for new antimicrobials for the adult population. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1037-1046.	1.3	8
134	Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 751-772.	0.9	8
135	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. <i>Microorganisms</i> , 2020, 8, 2010.	1.6	8
136	Clinical Features and Mortality of Nosocomial Candidemia in Very Old Patients: A Multicentre Italian Study. <i>Gerontology</i> , 2020, 66, 532-541.	1.4	8
137	Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care. <i>European Journal of Internal Medicine</i> , 2021, 94, 39-44.	1.0	8
138	Early versus late intubation in COVID-19 patients failing helmet CPAP: A quantitative computed tomography study. <i>Respiratory Physiology and Neurobiology</i> , 2022, 301, 103889.	0.7	8
139	Case report: Management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. <i>Journal of Medical Virology</i> , 2012, 84, 1340-1343.	2.5	7
140	Emergence of a KPC-3-Producing <i>Escherichia coli</i> ST69 as a Cause of Bloodstream Infections in Italy. <i>Microbial Drug Resistance</i> , 2015, 21, 342-344.	0.9	7
141	Judging the appropriate therapy for carbapenem-resistant <i>Acinetobacter</i> infections. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 135-138.	0.9	7
142	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa233.	0.4	7
143	Role of oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 96-108.	1.3	7
144	Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1290.e1-1290.e4.	2.8	7

#	ARTICLE	IF	CITATIONS
145	Innovative β -lactam/ β -lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria. <i>Future Microbiology</i> , 2022, 17, 393-396.	1.0	7
146	Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by <i>Staphylococcus aureus</i> : A Comprehensive Review of the Evidence. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 2137-2157.	1.1	7
147	Comment on: Mortality due to <i>Klebsiella pneumoniae</i> bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1743.1-1744.	1.3	6
148	Reduced Incidence of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections in Cardiac Surgery Patients after Implementation of an Antimicrobial Stewardship Project. <i>Antibiotics</i> , 2019, 8, 132.	1.5	6
149	Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study. <i>Antibiotics</i> , 2021, 10, 763.	1.5	6
150	New antibiotics for the treatment of nonfermenting Gram-negative bacteria. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 701-709.	1.3	6
151	Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-world Experience from the Liguria Region. <i>Journal of Clinical Medicine</i> , 2021, 10, 4682.	1.0	6
152	Culture-negative infective endocarditis (CNIE): impact on postoperative mortality. <i>Open Medicine (Poland)</i> , 2020, 15, 571-579.	0.6	6
153	Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 109-117.	1.3	6
154	Trends in the Incidence and Antibiotic Resistance of Enterococcal Bloodstream Isolates: A 7-Year Retrospective Multicenter Epidemiological Study in Italy. <i>Microbial Drug Resistance</i> , 2021, 27, 529-535.	0.9	5
155	Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 963-979.	2.0	5
156	The Use of Different Components of Brain Oxygenation for the Assessment of Cerebral Haemodynamics: A Prospective Observational Study on COVID-19 Patients. <i>Frontiers in Neurology</i> , 2021, 12, 735469.	1.1	5
157	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13358.	1.7	4
158	COVID-19: Some clinical questions after the first 4 months. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13326.	1.7	4
159	The COVID-19 insidious trick: Subjective perception of numbers. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13465.	1.7	4
160	Antiviral treatment selection for SARS-CoV-2 pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 985-992.	1.0	4
161	How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 5-8.	0.9	4
162	Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 649-656.	2.0	4

#	ARTICLE	IF	CITATIONS
163	Development of antibiotics for Gram-negatives: where now?. <i>Clinical Investigation</i> , 2011, 1, 211-227.	0.0	3
164	The diagnostic conundrum of bacterial infections in cirrhotic patients. <i>Liver International</i> , 2017, 37, 1411-1411.	1.9	3
165	Interpreting desirability of outcome ranking (DOOR) analyses in observational studies in infectious diseases: caution still needed. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1985-1986.	1.3	3
166	Is a step-down antiretroviral therapy necessary to fight severe acute respiratory syndrome coronavirus 2 in HIV-infected patients?. <i>Aids</i> , 2020, 34, 1865-1867.	1.0	3
167	Stewardship of Antibiotics for Multidrug-Resistant Gram-Negative Bacteria. <i>Antibiotics</i> , 2020, 9, 206.	1.5	3
168	Performance of Existing Definitions and Tests for the Diagnosis of Invasive Fungal Diseases other than Invasive Candidiasis and Invasive Aspergillosis in Critically Ill, Adult Patients: A Systematic Review with Qualitative Evidence Synthesis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 176.	1.5	3
169	A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic. <i>Drugs in Context</i> , 2020, 9, 1-2.	1.0	3
170	Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210957.	1.1	3
171	The Beta-d-glucan Test: Time to Re-Visit Its Utility in IFI Diagnosis. <i>Current Fungal Infection Reports</i> , 2015, 9, 292-301.	0.9	2
172	Prognostic Impact of Negative Serum (1,3)- β -D-glucan in Patients With Candidemia. <i>Clinical Infectious Diseases</i> , 2020, 71, 1124-1126.	2.9	2
173	Adequate duration of therapy in severe fungal infections. <i>Current Opinion in Critical Care</i> , 2020, 26, 466-472.	1.6	2
174	A Wide Database for Future Studies Aimed at Improving Early Recognition of Candidemia. <i>Studies in Health Technology and Informatics</i> , 2021, 281, 1081-1082.	0.2	2
175	The Role of PCSK9 in Infectious Diseases. <i>Current Medicinal Chemistry</i> , 2022, 29, 1000-1015.	1.2	2
176	Clinical significance of inflammatory markers of bacterial infection in critically ill patients with COVID-19 after treatment with anti-inflammatory and immunomodulatory drugs: a complex new scenario. <i>Frontiers in Bioscience</i> , 2021, 26, 405.	0.8	2
177	Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 487-498.	1.0	2
178	Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: An Italian National Survey (BADAS). <i>Antibiotics</i> , 2022, 11, 56.	1.5	2
179	Levels of beta-D-glucan in <i>Candida auris</i> supernatants, an <i>in vitro</i> and <i>in vivo</i> preliminary study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1154.e1-1154.e3.	2.8	2
180	Colistin versus colistin plus meropenem for severe infections. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 494-495.	4.6	1

#	ARTICLE	IF	CITATIONS
181	Epidemiology and outcome of <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>Klebsiella pneumoniae</i> (KPC-KP) infections in cardiac surgery patients: a brief narrative review. <i>Journal of Chemotherapy</i> , 2019, 31, 359-366.	0.7	1
182	Role of Antifungal Therapy in Complicated Intra-abdominal Infections. <i>Current Infectious Disease Reports</i> , 2020, 22, 1.	1.3	1
183	A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2022, 11, 635-638.	1.8	1
184	<i>Mycobacterium tuberculosis</i> Surgical Site Infection after Cardiac Surgery in the COVID-19 Era: A Case Report. <i>Infectious Disease Reports</i> , 2022, 14, 101-105.	1.5	1
185	Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study. <i>Antibiotics</i> , 2021, 10, 1554.	1.5	1
186	A Wide Database for a Multicenter Study on <i>Pneumocystis jirovecii</i> Pneumonia in Intensive Care Units. <i>Studies in Health Technology and Informatics</i> , 2022, , .	0.2	1
187	Factors Associated With Lack of Viral Suppression at Delivery. <i>Annals of Internal Medicine</i> , 2015, 162, 874.	2.0	0
188	eReply. Diagnostic intricacies and fortuitous treatment approaches for carbapenem-resistant <i>Klebsiella pneumoniae</i> . <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 23, 768.2-768.	0.5	0
189	Commentary: Human Immunodeficiency Virus and Allergic Bronchopulmonary Aspergillosis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw192.	0.4	0
190	Is initial serum (1,3)- β -d-glucan truly associated with mortality in patients with candidaemia? Authors' response. <i>Clinical Microbiology and Infection</i> , 2016, 22, 579.	2.8	0
191	147. Non-Fermenting Gram-Negative Bloodstream Infection: A Multicenter Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S101-S101.	0.4	0
192	Reducing dissemination of carbapenem-resistant <i>Klebsiella pneumoniae</i> . <i>Annals of Translational Medicine</i> , 2019, 7, S365-S365.	0.7	0
193	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0
194	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0